HK1218712A1 - 用於吸入施用的包含抗膽鹼能藥、皮質類固醇和β-腎上腺素能藥的干粉製劑 - Google Patents

用於吸入施用的包含抗膽鹼能藥、皮質類固醇和β-腎上腺素能藥的干粉製劑

Info

Publication number
HK1218712A1
HK1218712A1 HK16106687.7A HK16106687A HK1218712A1 HK 1218712 A1 HK1218712 A1 HK 1218712A1 HK 16106687 A HK16106687 A HK 16106687A HK 1218712 A1 HK1218712 A1 HK 1218712A1
Authority
HK
Hong Kong
Prior art keywords
betaadrenergic
anticholinergic
corticosteroid
inhalation
administration
Prior art date
Application number
HK16106687.7A
Other languages
English (en)
Inventor
‧穆薩
‧帕斯夸利
‧阿基斯-薩爾瓦爾
‧斯基亞雷蒂
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51292914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1218712(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of HK1218712A1 publication Critical patent/HK1218712A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16106687.7A 2013-07-11 2016-06-10 用於吸入施用的包含抗膽鹼能藥、皮質類固醇和β-腎上腺素能藥的干粉製劑 HK1218712A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13176114 2013-07-11
EP13194763 2013-11-28
PCT/EP2014/064824 WO2015004243A1 (en) 2013-07-11 2014-07-10 Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

Publications (1)

Publication Number Publication Date
HK1218712A1 true HK1218712A1 (zh) 2017-03-10

Family

ID=51292914

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106687.7A HK1218712A1 (zh) 2013-07-11 2016-06-10 用於吸入施用的包含抗膽鹼能藥、皮質類固醇和β-腎上腺素能藥的干粉製劑

Country Status (34)

Country Link
US (2) US9402825B2 (zh)
EP (3) EP3569222A1 (zh)
JP (1) JP6426167B2 (zh)
KR (2) KR20160029797A (zh)
CN (1) CN105338960B (zh)
AU (1) AU2014289185B2 (zh)
BR (1) BR112015030914B1 (zh)
CA (1) CA2917752C (zh)
CL (1) CL2016000028A1 (zh)
CY (2) CY1120806T1 (zh)
DK (2) DK3019153T3 (zh)
EA (1) EA029125B1 (zh)
ES (2) ES2867552T3 (zh)
GE (1) GEP20186853B (zh)
HK (1) HK1218712A1 (zh)
HR (2) HRP20182008T1 (zh)
HU (2) HUE039827T2 (zh)
IL (1) IL243507A0 (zh)
LT (2) LT3019153T (zh)
MX (1) MX2016000290A (zh)
MY (1) MY176176A (zh)
NZ (1) NZ715797A (zh)
PE (2) PE20212110A1 (zh)
PH (1) PH12016500043A1 (zh)
PL (2) PL3019153T3 (zh)
PT (1) PT3019153T (zh)
RS (2) RS61652B1 (zh)
SA (1) SA516370373B1 (zh)
SG (1) SG11201600110RA (zh)
SI (2) SI3409270T1 (zh)
TN (1) TN2016000007A1 (zh)
TW (1) TWI642450B (zh)
UA (1) UA116907C2 (zh)
WO (1) WO2015004243A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079726A1 (es) * 2009-12-23 2012-02-15 Chiesi Farma Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
KR101786586B1 (ko) * 2012-01-25 2017-10-18 키에시 파르마슈티시 엣스. 피. 에이. 흡입에 의한 투여를 위한 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제
PE20212110A1 (es) * 2013-07-11 2021-11-04 Chiesi Farm Spa Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
JP6600961B2 (ja) * 2015-03-30 2019-11-06 ブラザー工業株式会社 表示制御装置、表示制御方法及び記憶媒体
KR102356120B1 (ko) * 2015-05-01 2022-01-28 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 다중 약물 취성 매트릭스 조성물
MA52437A (fr) 2015-11-16 2021-05-05 Chiesi Farm Spa Une formulation de poudre sèche contenant un anticholinergique, un corticoïde et un bêta-adrénergique
DK3377108T3 (da) * 2015-11-16 2020-04-20 Chiesi Farm Spa Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
JP2019535708A (ja) * 2016-11-10 2019-12-12 メディスカ ファーマシューティック インコーポレイテッド 薬剤の配合方法およびシステム
EP3621589B1 (en) * 2017-05-11 2021-07-07 Chiesi Farmaceutici S.p.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2018206618A1 (en) 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
BR112022004970A2 (pt) 2019-09-24 2022-08-23 Chiesi Farm Spa Formulação de pó seco, processo para preparar uma formulação de pó seco e inalador de pó seco
US20240050382A1 (en) * 2022-08-11 2024-02-15 De Motu Cordis Pty Ltd Inhalable Epinephrine Formulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
ATE382386T1 (de) 1998-11-13 2008-01-15 Jagotec Ag Multidosis-trockenpulverinhalator mit pulverreservoir
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
DE60131399T3 (de) * 2000-06-27 2019-11-14 Vectura Ltd. Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung
EP2298279B1 (en) * 2000-11-30 2018-11-14 Vectura Limited Pharmaceutical compositions for inhalation
DK1386630T3 (da) 2002-07-31 2006-09-11 Chiesi Farma Spa Pulverinhalator
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
AR079726A1 (es) * 2009-12-23 2012-02-15 Chiesi Farma Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
KR101738712B1 (ko) 2009-12-23 2017-05-22 키에시 파르마슈티시 엣스. 피. 에이. Copd용 조합요법
TR201000681A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
CA2794941C (en) * 2010-04-01 2018-05-15 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
UA111470C2 (uk) * 2010-04-21 2016-05-10 К'Єзі Фармачеутічі С.П.А. Спосіб отримання частинок зі зменшеними електростатичними зарядами
AU2011269238A1 (en) * 2010-06-22 2013-01-10 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
KR101786586B1 (ko) * 2012-01-25 2017-10-18 키에시 파르마슈티시 엣스. 피. 에이. 흡입에 의한 투여를 위한 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PE20212110A1 (es) * 2013-07-11 2021-11-04 Chiesi Farm Spa Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion

Also Published As

Publication number Publication date
TW201536352A (zh) 2015-10-01
IL243507A0 (en) 2016-02-29
PE20212110A1 (es) 2021-11-04
LT3409270T (lt) 2021-07-26
CY1120806T1 (el) 2019-12-11
PE20160372A1 (es) 2016-05-19
TN2016000007A1 (en) 2017-07-05
MX2016000290A (es) 2016-04-13
GEP20186853B (en) 2018-05-25
PL3019153T3 (pl) 2019-02-28
NZ715797A (en) 2020-06-26
CA2917752C (en) 2022-05-03
JP2016523950A (ja) 2016-08-12
AU2014289185A1 (en) 2016-02-04
EA029125B1 (ru) 2018-02-28
US20150017248A1 (en) 2015-01-15
EP3409270A1 (en) 2018-12-05
RS57799B1 (sr) 2018-12-31
US9402825B2 (en) 2016-08-02
BR112015030914A2 (zh) 2017-07-25
CN105338960B (zh) 2019-06-04
PT3019153T (pt) 2018-12-04
DK3409270T3 (da) 2021-04-26
JP6426167B2 (ja) 2018-11-21
AU2014289185B2 (en) 2019-05-23
SG11201600110RA (en) 2016-02-26
KR102275904B1 (ko) 2021-07-13
US20160263027A1 (en) 2016-09-15
MY176176A (en) 2020-07-24
HRP20210704T1 (hr) 2021-06-11
CA2917752A1 (en) 2015-01-15
EP3019153A1 (en) 2016-05-18
HUE053957T2 (hu) 2021-08-30
HUE039827T2 (hu) 2019-02-28
EP3019153B1 (en) 2018-09-05
CN105338960A (zh) 2016-02-17
SA516370373B1 (ar) 2017-10-11
EP3409270B1 (en) 2021-02-24
BR112015030914B1 (pt) 2023-04-04
PH12016500043B1 (en) 2016-03-28
ES2699986T3 (es) 2019-02-13
DK3019153T3 (en) 2018-11-19
SI3019153T1 (sl) 2018-12-31
US9808422B2 (en) 2017-11-07
CY1123937T1 (el) 2022-05-27
UA116907C2 (uk) 2018-05-25
WO2015004243A1 (en) 2015-01-15
KR20160029797A (ko) 2016-03-15
HRP20182008T1 (hr) 2019-01-25
PH12016500043A1 (en) 2016-03-28
RS61652B1 (sr) 2021-04-29
EA201690006A1 (ru) 2016-07-29
PL3409270T3 (pl) 2021-08-09
SI3409270T1 (sl) 2021-07-30
CL2016000028A1 (es) 2016-08-05
ES2867552T3 (es) 2021-10-20
TWI642450B (zh) 2018-12-01
EP3569222A1 (en) 2019-11-20
LT3019153T (lt) 2018-11-26
KR20210075217A (ko) 2021-06-22

Similar Documents

Publication Publication Date Title
HRP20182008T1 (hr) Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom
HRP20181550T1 (hr) Formulacija suhog praška koja sadrži kortikosteroid i beta-adrenergik za davanje inhalacijom
PT3409270T (pt) Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação